Group items matching

in title, tags, annotations or url

Two pharmacies in Rotherham are set to merge into one, if plans are approved by NHS England. Weldricks Pharmacy has applied to merge its two Swinton branches, on Church Street and the Crown Street Surgery. If approved, the branch on Church Street will be modernised, and additional consulting rooms will be added, while the Crown Street site will be closed. Rotherham Met Borough Council's health and wellbeing board are set to make a representation supporting the plans, and say that analysis by public health "outlines the very minimal impact that this change will have in terms of pharmacy access in the borough based on the service offer, opening hours and walking times to this branch and the main pharmacy." They say the current opening hours will remain the same, and there will be no disruption to services during the consolidation. A statement from Weldricks adds that the decision to merge is down to funding cuts, and the company could go out of business if operating costs are not reduced - 'despite having been a local, family-owned business for almost 100 years'.

Community pharmacies in Cornwall have delivered more than 8000 face-to-face consultations over last 12 months. Walk In Consultation Service (WICS) began 12 months ago when pharmacies in Cornwall started offering face-to-face consultations for a wide range of minor ailments, and NHS treatment as required - the first service of its kind in England. Cornwall & Isles of Scilly Scilly Local Pharmaceutical Committee (LPC) Chief Officer Nick Kaye joined Operations Manager Drew Creek in Parliament recently by invite of Steve Double MP, St Austell and Newquay to meet with Minister for Health Neil O'Brien MP to present the service to them and Senior Civil Servants from DHSC and NHSE with a view to rolling this service out nationally. The data from these consultations show that over 6000 GP appointments were averted as a result of the service being available. After each consultation a record was sent to the patient's GP for information.

Simon Harris bought an average-sized store from a national chain and turned it into a profitable business in just over a year - a great example of how to start up a pharmacy and become successful. His formula was quite simple - recognise the available opportunities, take some calculated risks and reap the rewards. Simon went into pharmacy because he felt it was a profession that would allow him to "help people" and have a direct impact on their lives. "I also thought it was a profession which would allow me to have my own business one day." Since qualifying as a pharmacist from Bath University in the late 90s, Simon did his pre-reg at a large Boots store in Broadmead, where we had some "great experience" as a pharmacist manager. He decided to take a year out and went around the world with his "now wife" and ended up working as a pharmacist for a pharmacy group Down Under which had a contract with the sports industry, i.e. Australian Open and the Australian Football League. "It was quite an experience because at the time I knew nothing about Aussie football but I ended up being their pharmacist after a short conversion course."

The Royal Pharmaceutical Society (RPS) has welcomed the appointment of Michael Matheson MSP as Cabinet Secretary for NHS Recovery, Health and Social Care in Scotland. Commenting on the announcement Laura Wilson, Director of RPS Scotland, said: "I would like to congratulate Michael Matheson on being appointed to this position. NHS recovery is vitally important, and pharmacy has a huge amount to offer this agenda. "Our current priorities include enabling pharmacists to take leadership of prescribing in all care settings, tackling health inequalities and advocating for change, implementing shared patient records between healthcare professionals to provide high-quality, person centred and safe patient care, improving pharmacists' wellbeing and tackling the climate emergency by encouraging sustainable and green prescribing across Scotland.

Indian authorities have cancelled or suspended licences of some domestic drug companies as part of action taken against 76 pharmaceutical firms this month for selling adulterated or fake products, a government source said on Thursday. India is known as the 'pharmacy of the world' and its pharmaceuticals exports have more than doubled over the past decade to $24.5 billion in 2021-22. But that image has been dented by the death of at least 70 children in Gambia and 19 children in Uzbekistan in Uzbekistan last year linked to drugs made by India-based pharmaceutical companies. Health Minister Mansukh Mandaviya confirmed a crackdown but did not give details of companies against which action had been taken. "There are more than 10,500 pharma companies in the country. Companies who make spurious medicine will not be spared," Mandaviya told reporters at an event. Licences of some Indian drug companies have been cancelled, some were suspended while others have been put on notice during the past 15 days, the source, who had direct knowledge of the matter, told Reuters news agency.

Boots witnessed a 'record-breaking' performance for beauty driving retail sales with a growth of 16 per cent in the three months to 28 February 2023. The beauty category delivered a record January, and premium beauty saw its biggest ever sales week in December. Skincare reported three consecutive weeks of record sales in December driven by the 'expert skincare' category in which brands including No7, La Roche-Posay, CeraVe and Eucerin proved popular. Boots beauty transformation strategy continued with 19 new beauty halls opened in Q2 and the 170th store to receive a beauty makeover opening at Westfield White City post-period end. Boots now stocks over 500 big name and cult beauty brands and exclusively sells the UK's leading skincare brand, No7. The business reported its eighth consecutive quarter of market share growth with gains across all categories, led by beauty - the stand-out performer of the quarter. Footfall, basket size and the number of Advantage Card customers all increased, as more people chose to shop at Boots. The Christmas period was particularly strong with retail sales in the five weeks to 31 December up 17.4% and outperforming the market. Boots further expanded its value offering in the quarter, announcing its biggest ever savings as part of its continued focus on the affordability of life's essentials. This included the addition of 60 new products to the Boots Everyday label as well as the extension of its Price Advantage scheme, which has to date resulted in £30 million of customer savings and now includes discounts on over 800 products every month.

The National Pharmacy Association (NPA) Board has elected 14 Board members on Friday (30 March) that will govern the association for next two years. Four new Board members have been elected while five previous members left the Board after serving their terms. The period April 2023 to March 2025 will see the completion of the transition to the new Board structure. The Board will meet again on Monday (24 April) to elect the Chair and other appointments. Gareth Jones, Returning Officer for the NPA Board elections, said: "The NPA has undertaken a process of significant modernisation of organisational governance over the past years. Key elements of this process include adopting modern new Articles of Association, reforming the structure of the Board and introducing term limits. The process of electing the Board has also been changed so that half of the Board will be up for election every two years - which supports continuity and reduces the risk of a loss of organisational memory." "Recognising that the Board would already be losing a lot of organisational memory in 2023 with five members of Board standing down, the Board determined that three individuals should be co-opted onto the new Board as the process of transformation continues. In March 2025, anyone that has served 12 years or more will be required to stand down."

The current structure of global incentives to develop new antibiotics is insufficient and requires urgent resolution revealed a new report 'Incentivising new antibiotics' by the Office of Health Economics (OHE). OHE analysis demonstrates that on a global level, it is estimated that an effective 10-year incentive would require £3.5bn ($4.2bn) to adequately cover the entire research and development process for a new antibiotic. The report considers how health systems in the UK and around the world can stimulate the research and development (R&D) of new antibiotics. In 2020, the National Institute for Health and Care Excellence (NICE) and NHS England initiated an Antimicrobial Resistance pilot with the aim of incentivising pharmaceutical companies to develop new antibiotics by addressing the issues associated with reimbursement, which historically has deterred companies from pursuing AMR research.

Generic and over-the-counter drugs company Stada has asked the German government to seek assurances from Ukraine that the company can continue operations there even though it also does business in Russia. In a March 21 letter to German Economy Minister Robert Habeck, Stada CEO Peter Goldschmidt said there was a risk Kyiv might withdraw the company's market authorisation. Stada "still has no longer-term certainty that we will be able to sell our products in Ukraine in the future," the letter said, with the subject line: "Please prevent the exclusion of international pharmaceutical companies from the Ukrainian market." The Economy Ministry did not have an immediate comment on the letter. Habeck promised investment guarantees for German companies during a trip to Ukraine on Tuesday (April 4) as part of his goal to speed up reconstruction in the war-torn country. Goldschmidt said restricting Stada's operations would be bad for Ukraine.

The Department of Health in Northern Ireland has advised pharmacies to continue providing rota services on Easter after learning that many pharmacies are unwilling to provide the services on Easter holidays. "It is extremely regrettable that community pharmacy representatives have advised that access to rota pharmacies in some parts of Northern Ireland will be reduced over the Easter holidays," department said. They have also stated that despite a commitment of recurrent investment, support for new patients assessed by Trusts as requiring blister packs may be restricted. These actions have the potential to impact on patients and other parts of the Health and Social Care system. The department has also called the CPNI's demand to increase the funding up to 50 per cent in the sector "unrealistic" in the current financial climate. It said: "Financial pressures across the entire NI public sector are severe with an extremely challenging health budget anticipated for 2023/24." "The Department is therefore facing a significant funding gap just to maintain existing services and the whole Health and Social Care system is an extremely unpredictable and fragile position. The core funding envelope available to community pharmacies in NI has increased by 16% over the past three years."

Bas Vorsteveld has been elected as the new president of PAGB, the trade association representing the manufacturers of branded OTC medicines, self care medical devices and food supplements. Vorsteveld, who is vice president and general Manager of Haleon GB and Ireland, succeeds Neil Lister, managing director UK & Ireland and vice president at Perrigo. PAGB said the appointment comes at a crucial time for the consumer healthcare association as it looks to expand the role of self-care, secure a long-term favourable business environment for members, adapt to environmental challenges and continue to deliver excellent services for members. "We are so pleased to welcome Bas to the role of President. Bas has been actively involved with PAGB as a board member and we're looking forward to continuing our work with him. I have already seen from Bas's time on our Board that he combines great sector knowledge with drive, energy and genuine passion for what we do and we're so excited to have him as our President," Michelle Riddalls, chief executive of PAGB, said. "Bas's input and guidance as our strategy evolves over the coming years will be vital as we respond to new challenges as they emerge and make the most of the opportunities ahead."

The National Pharmacy Association (NPA) has asked the Secretary of State for Health and Social Care to convene a 'medicines supply taskforce', following weeks of problems with antibiotics supplies. The NPA's chief executive Mark Lyonette wrote a letter to Steve Barclay this week. It cited the precedent of the HRT Taskforce which this summer brought together representatives from across the supply chain after months of supply problems affecting women. "We strongly believe that this situation calls for a similar response from the government. It is imperative that we resolve this supply situation urgently and therefore we request that you convene a Medicines Supply Taskforce, with all the relevant stakeholders in the supply chain, to urgently discuss and agree practical solutions to address the disruptions to the supply of medicines. HRT and antibiotics are the most visible examples of a wider problem with medicines supply which needs to be addressed." NPA board members Olivier Picard and Reena Barai were among the stakeholders joining meetings convened by the HRT Taskforce this summer.

Erectile dysfunction is a very common form of medical condition that occurs in males over time. Usually, this problem is found in people who take too much medication, and ED is probably a side effect of any one of them. However, in seventy-five percent of males, the cause of erectile dysfunction is unknown, and finding the accurate reason for it is very complex. It can be a result of any neural complications, diabetes, or any surgeries that include the prostate of our body. ED can also be treated by using a vacuum device and surgeries on the private parts. However, it can be eradicated completely without any surgeries, and here are some tips that will help you in overcoming erectile dysfunction without surgery and lead a happy life. DO EXERCISE Exercise is a great way to overcome any health issues, and also to safeguard yourself from health issues in the future. Physical activity also helps you in controlling obesity, which is one of the reasons behind ED. By not doing regular exercises, you expose yourself to various cardiovascular problems, which contribute to ED. Studies show that light aerobic exercise for 30-40 minutes a day for at least four times a week for at least 6 months has considerably reduced ED in people. STAY SLIM Studies have shown that a person who has a waist near 42 inches is more likely to suffer from ED than a person with a waistline of 32 inches. Therefore, if you are obese it's time that you lose some weight. Excessive fat in the body is the birthplace of various diseases. Obesity is also responsible for vascular problems and diabetes which are two primary causes of ED.

Leyla Hannbeck, chief executive of the Association of Independent Multiple Pharmacies has said pharmacists have been "struggling to obtain the very basic, most common cold and flu medicine." She told the PA news agency that the shortage wasn't around "just the branded medicines" but "also simple things like throat lozenges, cough mixtures or pain killers - particularly the ones that are soluble." Stating that the sector was finding it very difficult these shortages she said "those people who are in charge of supporting us with it are denying it." "The demand has been high because this season we've seen higher cases of colds and flu and people are obviously trying very hard to look after themselves and making sure that they use the relevant products to manage the symptoms.

German biotechnology company BioNTech has signed a deal with the Department of Health and Social Care to enrol up to 10,000 patients in clinical trials by the end of 2030 for personalised cancer therapies, the German drug maker said. The multi-year collaboration is focused on cancer immunotherapies based on mRNA or other drug classes, infectious disease vaccines, and investments into expanding the company's footprint in the UK, BioNTech said in a statement on Thursday (January 5). Under the agreement, the parties plan to utilise UK's clinical trial network, genomics and health data assets, aiming to enrol the first cancer patient in the second half of 2023, the company said.

Orphan Drug development specialist TMC Pharma has appointed Gordon Cameron to its board as a non-executive director. Mr Cameron has 25 years' board-level experience in biotech and pharmaceutical services sectors. He started his career with EY, then spent several years in investment banking at Rothschild before becoming CFO, and then CEO, of international vaccine company Acambis. For the past 15 years, Mr Cameron has been CFO of Quotient Sciences, an international Contract Development and Manufacturing Organisation and Clinical Research Organisation. In 2004, he was awarded the Officer of the Order of the British Empire for services to the British biotechnology industry. Julie Matthews, chief executive officer of TMC Pharma, said that the new appointment would "enhance our strategic capability and tactical execution as we consolidate our position as a global leader in the Orphan Drug development market."

In response to Thursday (5 January)'s announcement on the proposal of new 'anti-strike' legislation, the Pharmacists Defence Association (PDA) has said that it will work with other trade unions to defend the fundamental right for workers in the sector to strike. The association believes that "industrial action should always be a last resort, especially for health professionals such as pharmacists, however having the option to strike is a fundamental right for working people in a fair and free, civilised society." "The right to strike is a fundamental right through which employees can act collectively to secure and protect pay and conditions." It added: "The Trade Union Congress (TUC) are coordinating the challenge to these proposals." The TUC said in a statement: "The Prime Minister should concentrate on fixing our public services, not attacking public sector staff. The proposed legislation would make it harder for disputes to be resolved."

Anglo-Swedish drugmaker AstraZeneca said on Monday (January 9) that it had struck a deal to buy US-based drug developer CinCor Pharma for up to $1.8 billion to increase its stock of heart and kidney drugs. Core to the deal is CinCor's experimental therapy baxdrostat, which is in development to treat conditions including high blood pressure and chronic kidney disease. AstraZeneca aims to combine baxdrostat with its own Farxiga, a diabetes drug whose sales ballooned after it was also shown to benefit patients with heart failure and kidney disease. Farxiga, whose sales jumped by almost 50 per cent during the first nine months of 2022 to reach $3.2 billion, belongs to a highly competitive class of drugs that includes rivals such as Boehringer Ingelheim and Eli Lilly's Jardiance. AstraZeneca gets about a third of its revenue from cancer drugs, but its heart, kidney and diabetes medicines are its second most lucrative business by sales, generating roughly $6.9 billion of the drugmaker's total revenue of more than $33 billion in the first three quarters of 2022.

A community pharmacy, Barton Pharmacy located in Woolacombe, Devon has been sold to a local pharmacist and its previous employee, Harminder Chaggar, announced Christie & Co. The business has been owned by Mr Osman Hamid for the last seven years and was brought to market to allow him to concentrate on his other business interests. Barton Pharmacy is dispensing an average of 2,440 items per month. It lies completely unopposed in the highly desirable North Devon coastal village of Woolacombe, in an Area of Outstanding Natural Beauty, and is an ever-popular holiday destination which boasts 'Beach of the Year 2021' as voted for by The Sunday Times. Osman Hamid, previous owner of Barton Pharmacy, comments, "Owning this business for the last seven years has been an enjoyable experience, as we have had full support from the NHS as it has an attached LPS contract and receives an overwhelmingly generous OTC income which is more than the average pharmacy. The business has huge potential to grow and diversify into other avenues that are yet to be explored, and it is lovely to know that it has been passed onto a new owner operator that I trust will do well with the business moving forwards."

AAH Pharmaceuticals (AAH) has announced the appointment of Brain Chambers as Chief Commercial Officer. "I'm proud to lead the commercial functions in AAH in my new role and broader area of responsibility." Said Brian. "I'm committed to delivering on great value for our customers and building and strengthening our supplier partnerships." Brain is associated with AAH Pharmaceuticals for more than 14 years. He joined the organisation as Business Development Manager in October 2008. His previous role in the organisation was on Sales and Marketing Director. He posted on LinkedIn: "This is a big move for me personally, but that's a side hustle. What is the main play here is AAH becoming a standalone independent wholesale business focussed on only the AAH customer and our core business and this is just one part of that.